Fideuram Asset Management Ireland dac Takes $1.94 Million Position in Insmed, Inc. $INSM

Fideuram Asset Management Ireland dac bought a new stake in shares of Insmed, Inc. (NASDAQ:INSM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,158 shares of the biopharmaceutical company’s stock, valued at approximately $1,942,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. National Pension Service bought a new position in shares of Insmed during the 4th quarter valued at approximately $48,808,000. Northwestern Mutual Wealth Management Co. boosted its position in shares of Insmed by 277.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 430 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 316 shares during the last quarter. SBI Okasan Asset Management Co.Ltd. bought a new position in shares of Insmed during the 4th quarter valued at approximately $3,562,000. Intech Investment Management LLC bought a new position in shares of Insmed during the 4th quarter valued at approximately $562,000. Finally, Geode Capital Management LLC boosted its position in shares of Insmed by 14.4% during the 4th quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock valued at $751,936,000 after acquiring an additional 539,625 shares during the last quarter.

Insider Activity

In other news, insider Michael Alexander Smith sold 6,149 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $108.47, for a total value of $666,982.03. Following the completion of the sale, the insider owned 41,613 shares of the company’s stock, valued at approximately $4,513,762.11. This represents a 12.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the completion of the sale, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at $43,361,604.45. The trade was a 3.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 156,643 shares of company stock worth $24,513,766. 2.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on INSM shares. Leerink Partners increased their target price on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research report on Tuesday, March 24th. Stifel Nicolaus raised their price target on Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research note on Friday, May 8th. Barclays lifted their price objective on shares of Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Finally, Royal Bank Of Canada dropped their price objective on shares of Insmed from $220.00 to $205.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $210.95.

Insmed Price Performance

Shares of INSM stock opened at $106.91 on Friday. Insmed, Inc. has a twelve month low of $65.56 and a twelve month high of $212.75. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The stock has a fifty day simple moving average of $134.42 and a two-hundred day simple moving average of $158.11. The stock has a market capitalization of $23.17 billion, a price-to-earnings ratio of -18.59 and a beta of 0.89.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same period in the previous year, the company posted ($1.42) earnings per share. The firm’s quarterly revenue was up 229.7% on a year-over-year basis. On average, analysts predict that Insmed, Inc. will post -2.52 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.